Telomerase activity and its inhibition in benign and malignant breast lesions
Authors:
- 1 September 1997
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 183 (1) , 57-61
Abstract
Many types of human tumours and immortal cell lines have been demonstrated to exhibit telomerase activity with the recently formulated telomeric repeat amplification protocol (TRAP assay). However, a small proportion of undoubted tumour samples give a negative result and it has been postulated that, on occasion, the assay can be blocked by inhibitory factors in the cell or tissue extracts. To resolve this issue, a modified TRAP assay has been used to re‐examine 45 previously negative breast tissue specimens. Phenol–chloroform extraction of the sample after the telomerase extension reaction revealed the presence of polymerase chain reaction (PCR) inhibitory factors in tissue from 6 of 14 (43 per cent) breast biopsies of fibrocystic disease (FCD), 6 of 12 (50 per cent) fibroadenomas (FAs), none of five carcinomas in situ, and 1 of 13 (8 per cent) invasive carcinoma (CA) tissue specimens. These results demonstrated that the enzyme telomerase can be active in some benign lesions as well as in carcinomas of the breast. Specimens which still remained negative for telomerase in the above experiment were next assayed for the presence of biologically relevant inhibitors of the enzyme by mixing the extracts with confirmed positive samples. Extracts from 12 of 17 carcinoma specimens (all of five carcinomas in situ and 7 of 12 invasive carcinomas showed dose‐dependent inhibitory activity against telomere extension, whereas no inhibition was observed in those of three of eight FCD and 2 of seven FAs. These results indicate that telomerase activity may be regulated by a balance between inhibitory factors and an activated enzyme. © 1997 by John Wiley & Sons, Ltd.Keywords
This publication has 14 references indexed in Scilit:
- Telomerase activity in human breast cancer and benign breast lesions: Diagnostic applications in clinical specimens, including fine needle aspiratesInternational Journal of Cancer, 1996
- Re: Reductase Enzyme Expression Across the National Cancer Institute Tumor Cell Line Panel: Correlation With Sensitivity to Mitomycin C and EO9JNCI: Journal of the National Cancer Institute, 1996
- Do telomerase antagonists represent a novel anti-cancer strategy?British Journal of Cancer, 1996
- Telomerase activity in normal and malignant hematopoietic cells.Proceedings of the National Academy of Sciences, 1995
- Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivityNucleic Acids Research, 1995
- Telomerase Activity in Small-Cell and Non-Small-Cell Lung CancersJNCI: Journal of the National Cancer Institute, 1995
- Telomeres, Telomerase, and ImmortalityJNCI: Journal of the National Cancer Institute, 1995
- Correlating telomerase activity levels with human neuroblastoma outcomesNature Medicine, 1995
- Specific Association of Human Telomerase Activity with Immortal Cells and CancerScience, 1994
- A role for both RB and p53 in the regulation of human cellular senescence*1Experimental Cell Research, 1991